Antifungal medications play a critical role in managing fungal infections in pets, ranging from superficial conditions like dermatophytosis (ringworm) to systemic mycoses. Commonly used antifungals include azoles (e.g., fluconazole, itraconazole), allylamines (e.g., terbinafine), and polyenes (e.g., amphotericin B), each targeting fungal cell membranes through mechanisms such as ergosterol synthesis inhibition. These drugs are highly effective against infections like Malassezia dermatitis, aspergillosis, and cryptococcosis. Topical antifungals are preferred for localized infections, while systemic agents are reserved for severe or disseminated cases. Species-specific considerations are vital; for instance, itraconazole is often effective in cats, whereas ketoconazole may pose higher hepatotoxicity risks. While generally safe, systemic antifungals can cause dose-dependent adverse effects. Azoles may lead to gastrointestinal disturbances (vomiting, diarrhea) and hepatotoxicity, necessitating regular liver enzyme monitoring. Terbinafine is better tolerated but can still cause mild Gastrointestinal (GI) upset. Amphotericin B, used for life-threatening infections, carries risks of nephrotoxicity and requires careful hydration management. Topical formulations, though safer, may cause local irritation. Conclusion: Antifungal therapies are indispensable in veterinary medicine, offering significant benefits when tailored to individual pets. Balancing efficacy with potential risks requires vigilant monitoring and adherence to veterinary guidelines. Proper use ensures positive outcomes, mitigating the progression of fungal diseases while minimizing adverse health impacts.